Pipeline compound
Petrelintide
Petrelintide is a long-acting amylin analogue developed by Zealand Pharma and partnered with Roche. It is an investigational compound with no marketing authorisation in any territory. This profile is a mechanism and clinical-register summary for laboratory readers, with published statements reproduced as attributed quotations.
- Developer
- Zealand Pharma, in collaboration with Roche
- Also known as
- ZP8396
Mechanism
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. Its receptors are formed when the calcitonin receptor associates with receptor activity-modifying proteins (RAMP1, RAMP2 or RAMP3), producing the AMY1 to AMY3 receptor subtypes. This receptor family sits outside the incretin (GLP-1, GIP) axis, which is why amylin analogues are studied as a mechanistically separate line of enquiry rather than as a variation on GLP-1 receptor agonism.
Native human amylin is prone to aggregation, which historically limited its use as a research and clinical molecule. Analogue design in this class therefore focuses on sequence changes that reduce aggregation propensity while retaining receptor engagement, alongside modifications intended to extend the half-life to a once-weekly interval. Petrelintide is described by its developer as a long-acting amylin analogue on that basis.
Because petrelintide engages the calcitonin/amylin receptor family rather than GLP-1R, it is also studied in combination contexts alongside incretin agonists. Any statement about combination outcomes belongs to the trials that ran them, not to this page.
Clinical programme status
- Investigational. Petrelintide has no marketing authorisation in the United Kingdom, European Union or United States.
- Originated at Zealand Pharma under the development code ZP8396, and subsequently partnered with Roche for global development.
- Phase 2b results in the ZUPREME-1 study were reported by Roche in a company investor release on 5 March 2026. The figures below are reproduced verbatim from that release and are the company's own statements.
Published statements, quoted
Reproduced verbatim from the sources named. Peptx makes no claim of its own on these points.
“Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability”
Not yet stocked
Register interest
Petrelintide is not currently supplied by Peptx. Leave an email address and we will notify you once verified reference material is available. No purchase, no obligation, and the address is used for this notice only.
Frequently asked questions
- What is petrelintide?
- Petrelintide (development code ZP8396) is a long-acting amylin analogue developed by Zealand Pharma and partnered with Roche. It is investigational and not approved in any territory.
- Which receptors does petrelintide act on?
- The amylin receptor family, formed by the calcitonin receptor in complex with receptor activity-modifying proteins RAMP1 to RAMP3. This is a distinct receptor family from the GLP-1 receptor.
- Does Peptx stock petrelintide?
- No. Petrelintide is not currently supplied by Peptx. You can register an email address on this page to be notified if verified reference material becomes available.
- How does petrelintide differ from an incretin agonist?
- Incretin agonists such as semaglutide act at the GLP-1 receptor. Petrelintide acts at the amylin receptor family, a separate class B G-protein-coupled receptor complex.